Health professional and patient

Hundreds to benefit as NICE recommends first NHS treatment for advanced cervical cancer in over a decade

Hundreds of NHS patients with advanced cervical cancer are set to benefit from better healthcare after the National Institute for Health and Care Excellence (NICE) approved the first new treatment for the disease in 14 years.

The life-extending treatment comes in the form of the immunotherapy drug pembrolizumab, which is already offered by the health service in England to treat breast, bowel, lung and skin cancer.

The new treatment has been made available through the Cancer Drugs Fund and will benefit approximately 400 people over the next three years, according to NHS England.

The treatment is administered via an injection and, in conjunction with chemotherapy, works to stimulate a patient’s immune system by targeting and ultimately blocking a protein called PD-L1 on certain immune cells’ surfaces.

Although NICE has not been able to accurately establish the cost-effectiveness of the drug, initial clinical trial findings have indicated that, under the treatment, a patient’s cancer takes longer to get worse than compared to standard care. It has also suggested that it increases a patient’s life expectancy, though the extent to either has not yet been ascertained.

“Pembrolizumab shows promise as the first effective immunotherapy [against advanced cervical cancer],” NICE’s Director of Medicines Evaluation, Helen Knight said. “However, to ensure the best use of limited public funding, we need additional evidence to fully analyse its clinical and cost effectiveness before it can be considered for routine NHS use.”

Cancer Research UK estimates that, every year in England, around 2,600 women are diagnosed with cervical cancer with the most affected group being 30-34-year-olds. This leads to nearly 700 people dying a year from the disease in England, according to the NHS.

NHS England’s Director of Specialised Commissioning, John Stewart, described the move as a “significant step forward” whilst Health Minister Helen Whately said the news was a “win for women”.

NHE Nov/Dec 2023

NHE Nov/Dec 2023

AI is key in helping dementia patients live independently for longer.

The Nov/Dec 2023 edition of NHE brings you expert comment and analysis on a range of key health sector topics, from digital transformation to navigating post-pandemic challenges.


View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Events

NHE has created a full calendar of events to address the most important issues that influence the delivery of healthcare services. Over 365 days you'll have the opportunity to hear from a range of highly motivating, informative and inspirational speakers. These speakers will equip you with the knowledge and unique insight to enable you to overcome the challenges that you face.

National Health Executive Podcast

Ep 39.
What makes a good NHS manager? with Anthony Painter, Director of Policy at Chartered Management Institute (CMI)

In episode 39 of the National Health Executive podcast, we were joined by Anthony Painter, who is the director of policy at the Chartered Management Institute (CMI), to discuss all things management within the UK health sector and NHS.

During the podcast, Anthony shared some of the recent research CMI conducted in partnership with the Social Market Foundation, which centred around the state of management and leadership within the NHS.

More articles...

View all